Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

ABSTRACT: Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be challenging in the absence of clear categorization and standardization across oncology, endocrinology and other specialties. While existing guidelines provide some broad directions to diagnosis and management, they lack clarity on irAE-specific symptom evaluation and work-up, as well as assessment of severity. These limitations can then impact triage, time-sensitive management and care escalation to specialists such as oncoendocrinologists. The objective of this study was to develop consensus-based statements on disease definitions for E-irAEs.A

SUBMITTER: Zhu L 

PROVIDER: S-EPMC12530408 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature